Jonathan H Schatz
Overview
Explore the profile of Jonathan H Schatz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coughlin C, Chahar D, Lekakis M, Youssfi A, Li L, Roberts E, et al.
Blood Cancer J
. 2025 Feb;
15(1):9.
PMID: 39894894
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline combination chemoimmunotherapy, DLBCL carries persistently poor prognosis...
2.
Alderuccio J, Alencar A, Schatz J, Kuker R, Pongas G, Reis I, et al.
Lancet Haematol
. 2024 Dec;
12(1):e23-e34.
PMID: 39662486
Background: Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with...
3.
Diamond B, Chahar D, Jain M, Poos A, Durante M, Ziccheddu B, et al.
bioRxiv
. 2024 Nov;
PMID: 39605649
Ionizing radiotherapy (RT) is a widely used palliative and curative treatment strategy for malignancies. In solid tumors, RT-induced double strand breaks lead to the accumulation of indels, and their repair...
4.
Lightfuss O, Kumar P, Li L, Shastri T, Newsam A, Manara P, et al.
bioRxiv
. 2024 Nov;
PMID: 39484514
Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma and the most frequently diagnosed hematologic malignancy in the United States. DLBCL exhibits significant molecular and clinical heterogeneity, and...
5.
Manara P, Newsam A, Saralamma V, Russo M, Martinez A, Fattakhov N, et al.
bioRxiv
. 2024 Sep;
PMID: 39314323
Cancers coopt stress-response pathways to drive oncogenesis, dodge immune surveillance, and resist cytotoxic therapies. Several of these provide protection from ferroptosis, iron-mediated oxidative cell death. Here, we found dramatic sensitization...
6.
Trabolsi A, Arumov A, Schatz J
Blood Cancer J
. 2024 Feb;
14(1):27.
PMID: 38331870
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory...
7.
Newsam A, Coughlin C, Trabolsi A, Schatz J
Leuk Lymphoma
. 2023 Nov;
64(14):2217-2224.
PMID: 37933565
Chimeric antigen receptor T-cell therapy targeting CD19 (CAR-19) promotes impressive durable remissions for relapsed or refractory (rel/ref) large B-cell lymphoma (LBCL) patients with historically poor prognoses. Despite this, over half...
8.
Major A, Yu J, Shukla N, Che Y, Karrison T, Treitman R, et al.
Blood Adv
. 2023 Apr;
7(16):4528-4538.
PMID: 37026796
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy...
9.
Ho J, Cunningham T, Krieger J, Schatz J, Lee S
STAR Protoc
. 2023 Jan;
3(4):101919.
PMID: 36595908
Here, we present a protocol using MATRIX (mass spectrometry analysis of active translation factors using ribosome density fractionation and isotopic labeling experiments) platform to investigate changes of the protein synthesis...
10.
Jain M, Ziccheddu B, Coughlin C, Faramand R, Griswold A, Reid K, et al.
Blood
. 2022 Apr;
140(5):491-503.
PMID: 35476848
CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved for use against large B-cell lymphomas. Although host inflammatory and tumor microenvironmental markers associate with efficacy and resistance, the...